Leerink Partners Cut Price Target on Alnylam Pharma (ALNY) to $120 Following 4Q Earnings
Tweet Send to a Friend
Leerink Partners maintained an Outperform rating on Alnylam Pharmaceuticals (NASDAQ: ALNY), and cut the price target to $120.00 (from $152.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
